SEC Filing Summary

Daniel J. Starks, a director at Abbott Laboratories, reported a series of transactions on April 24 and April 27, 2026. On April 24, Starks acquired 2,286 restricted stock units (RSUs) with a reported value of $0, as these were granted under the Abbott Laboratories 2026 Incentive Stock Program and will be paid in common shares upon separation from service, death, or change in control. Additionally, an option to buy 7,105 common shares was granted with an exercise price of $91.86. On April 27, Starks sold 10,000 common shares at a weighted average price of $92.6537, with prices ranging from $92.43 to $93.04. Following these transactions, Starks directly holds 6,751,103 shares. The filing also notes 258 shares held indirectly through the Alynne Starks 2012 Irrevocable Trust, for which Starks is the sole trustee.